---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250611"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:12:34.723455+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms

## Summary
- At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).
- Median heartburn-free nights: 70.4% (10 mg), 71.0% (20 mg), 45.5% (placebo) over 4 weeks.
- Separation from placebo observed after first dose: 45.3% (10 mg) and 52.4% (20 mg) heartburn-free night vs 32.1% placebo.
- Symptom relief sustained through 20-week active extension; median heartburn-free nights remained above 70%.
- VOQUEZNA generally well tolerated; most common AEs (≤5%) included URI, sinusitis, influenza, UTI, nausea.

## SEC filing metadata
- accession: 0001193125-25-250611
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525250611/0001193125-25-250611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525250611/d62248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250611
- JSON: https://secwatch.observer/filing/0001193125-25-250611.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.